We are investigating whether a new treatment combining Zanubrutinib with Rituximab can improve nerve function in patients with IgM monoclonal gammopathy and related nerve damage. The study will also look at safety and how well patients tolerate the treatment.
Health conditions and diseases that the clinical trial is designed to study and treat.
Anti-MAG neuropathy is a rare neurological disorder caused by antibodies against myelin-associated glycoprotein, often linked to IgM monoclonal gammopathy. It leads to damage in the peripheral nerves, resulting in various symptoms.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.